ABSTRACT
Objective: To compare the differences of contents of effective components triolein and coixol in Coix lacryma-jobi var. mayuen from different origins. Methods: The Discover C18 column was used for the detection of triolein with mobile phase of acetonitrile-dichloromethanol (66:34). The flow rate of mobile phase was 0.7 mL/min. The column temperature was controlled at 30℃. The ELSD was used. The tube temperature was 45℃, and the flow rate of nitrogen was 1.5 L/min. The Agilent Zorbax SB-C18 column was used for the detection of the coixol with the mobile phase of acetonitrile-water (25:75), a flow rate of 1 mL/min, a temperature of 25℃ and a wavelength of 232 nm. Results: The triolein content of Zhejiang province was the highest, at 1.04%, and the lowest was in Hainan Province, which was 0.53%; The highest coixol content was in Shanghai, reaching 3.469 7 mg/g, but the lowest content was only 0.619 3 mg/g in Anhui province. Conclusion: The contents of triolein and coixol in adlay from eight Provinces are significantly different, the contents of triolein and coixol in adlay from Zhejiang and Fujian Provinces were relatively high, and medicinal material quality is better.
ABSTRACT
Objective To investigate the prevention and cure effect of anisodamine gel on phlebitis caused by intravenous infusion of KLT. Methods 96 patients with intravenous infusion of KLT were divided into the experimental group and the control group, 48 patients in each group, and the skin at the top of transfusion puncture points of the patients of the experimental group was evenly embrocated with 2% anisodamine gel along the vein before 3 to 5 minutes of intravenous infusion of KLT, while the control group was without any treatment. After observing the situation of venous injury, the skin at the top of transfusion puncture points of the positive patients would be embrocated with 2% anisodamine gel. The incidence, degree of phlebitis and treatment effect were compared between the two groups. Results The incidence rate of phlebitis of the control group was 68.7%, of which grade II, III occupied 60.4%, while the incidence rateof phlebitis of the experimental group was 10.4%, in which there was no occurrence of grade II, III phlebitis. All the venous injury symptoms of 33 patients of the control group and 5 patients of the experi -mental group disappeared after treatment, and after statistical processing, the incidence rate of phlebitis in the experimental group and the control group showed significant differences. Conclusions The embrocating of 2% anisodamine gel can effectively avoid the occurrence of the phlebitis caused by intravenous infusion of KLT.
ABSTRACT
Objective To investigate the effects of KLT on apoptosis of HepG2 cells and expression of Bcl-2 and Capase-8. Methods The cell fine HepG2 was induced by diverse density of KLT, and HepG2 cell was collected respectively after induction of 12 h, 24 h, 48 h. The control group was installed simulta-neon]y. The cell apoptosis and the expression of Bcl-2 and Caspase-8 were detected by flow cytometry (FCM). Results KLT can induce the apoptosis of HepG2 cell significantly, and the longer time past, the more apoptosis of HepG2 was. KLT can increase the expression of Caspase-8, but ineffective to Bcl-2. Con-clusion KLT can significantly induce the apoptosis of HepG2 cell through regulating the expression of Caspase-8.
ABSTRACT
Background : A vitamin K<SUB>2</SUB> agent has recently been approved and is going to be marketed for the treatment of osteoporosis. Since vitamin K<SUB>2</SUB> agents are known to cause rebound of blood coagulation capacity lowered by an anticoagulant warfarin, a great caution is necessary for the concomitant use of these agents.<BR>Objective and Design : A drug utilization survey to examine the use of warfarin and drugs for osteoporosis.<BR>Methods : Fukui Medical School Database was surveyed to identify patients who used warfarin and/or drugs for osteoporosis during the period between January 1, 1988 and July 31, 1995. Patients with a diagnosis osteoporosis made between December 1, 1983 and July 31, 1995, were also identified and their prescription data were extracted to examine the combined use of warfarin and drugs for osteoporosis. In addition, 53 outpatients with cardiovascular diseases were interviewed to know the treatments and medications given by other clinics.<BR>Results : Concomitant drug therapy for osteoporosis was given to 6.9% (56/813) of warfarin users. The proportion of concomitant use was 15% (36/234) in women, much higher than 3.5% (20/579) in men. More than 10% of the interviewed patients were receiving some treatments in other orthopedic clinics for osteoporosis or other diseases but few patients were aware of their medication.<BR>Conclusion : Old female users of warfarin, especially those having osteoporosis concomitantly, are likely to berome a high risk group for the possible interaction between warfarin and the vitamin K<SUB>2</SUB> agent. Useful information on the safety associated with the interaction between these two drugs should be given to this group of patients as well as to the prescribers and dispensers.